21世纪经济报道记者柳宁馨 杭州报道 重新审视中国制造业的路径，除了商业和技术，还可以从设计生态、消费时代等多体系出发，甚至可能诞生出一个划时代的智 能产品。 12月12日，第十届中国设计智造大奖(Design Intelligence Award，简称"DIA")颁奖典礼在中国美术学院良渚校区举行。DIA奖项 已迎来第十年，广泛走向全球科技行业，十届大奖累计参赛作品已超65000件，覆盖全球87个国家和地区，涵盖人工智能、生命 健康、数字制造、智慧城市等多个前沿领域，多个项目走向产业化。 21世纪经济报道记者采访了不少获得本届DIA大奖的设计师，他们来自不同的企业，却对智能时代的工业设计有一定共识，产 品设计从来不是单纯的技术堆砌或功能叠加，而是立足用户体验、融合人文情感与系统思维的综合创造，既要坚守对品质的极 致追求，也要有开放的系统视野。 日前，中央经济工作会议将"深化拓展'人工智能+',完善人工智能治理"作为明年要抓好的重点任务之一。"十五五"规划建议提 出，全面实施"人工智能+"行动，加强人工智能同产业发展、文化建设、民生保障、社会治理相结合，抢占人工智能产业应用制 高点，全方位赋能千行百业。 在这 ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2025-052 深圳迈瑞生物医疗电子股份有限公司 关于实际控制人之一、董事长增持计划实施完成的公告 李西廷先生保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、增持计划的基本情况：深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"） 于2025年11月27日披露了《关于实际控制人之一、董事长首次增持公司股份及后续增持计 划的公告》（公告编号：2025-051），基于对公司内在价值的认可和未来持续发展的坚定信 心，践行共同促进资本市场高质量发展的社会责任，公司实际控制人之一、董事长李西廷 先生，计划自2025年11月27日起6个月内通过集中竞价交易方式增持公司股份，拟增持金额 为人民币2亿元（含交易费用）。 2、增持计划实施完成情况：按照增持计划，李西廷先生已于2025年12月12日提前完成 本次增持计划，充分体现了对公司发展前景的坚定信心。增持计划实施情况具体如下：2025 年11月27日至2025年12月1 ...

FANGDA PARTNERS http://www.fangdalaw.com | E-mail: | email@fangdalaw.com | | --- | --- | | Tel.: Fax: | 86-755-8159-3999 86-755-8159-3900 | | 中国深圳市福田区中心四路1号 嘉里建设广场T1座9楼 邮政编码：518048 | | | 电子邮件 电 话 传 真 | | 9/F, Tower One, Kerry Plaza 1 Zhong Xin Si Road Futian District Shenzhen 518048, China 上海市方达（深圳）律师事务所 关于实际控制人增持 深圳迈瑞生物医疗电子股份有限公司股份的 法律意见书 致：深圳迈瑞生物医疗电子股份有限公司 上海市方达（深圳）律师事务所（以下简称"本所"）是具有中华人民共和 国境内法律执业资格的律师事务所。本所受深圳迈瑞生物医疗电子股份有限公 司（以下简称"迈瑞医疗"或"公司"）的委托，就迈瑞医疗实际控制人李西廷先 生（以下简称"增持人"）自2025年11月27日至2025年12月12日期间内（以下简称" ...

Core Viewpoint - The article emphasizes the importance of identifying companies with strong intrinsic value growth over the long term, despite short-term market volatility and valuation fluctuations [1][2][3]. Group 1: Investment Strategy - The investment strategy involves focusing on companies with strong intrinsic value growth, which is a compounding variable that can withstand market fluctuations over time [2][4]. - The article discusses the importance of distinguishing between short-term valuation changes and long-term value growth, highlighting that exceptional companies can outperform mediocre ones over extended periods [2][4]. - It suggests that finding companies with sustainable high intrinsic value growth simplifies the complex task of navigating market uncertainties [3][5]. Group 2: Characteristics of Good Businesses - Good businesses are defined by three key characteristics: high value, strong dependency, and significant growth potential [6][8]. - High value refers to a company's ability to significantly outperform industry standards, which can change over time due to various factors such as technological advancements and policy shifts [6][7]. - Strong dependency can arise from unique products or high switching costs, leading to a natural market lock-in effect [7][8]. - Significant growth potential is essential for providing high investment returns over the long term [8][9]. Group 3: Characteristics of Good Companies - Good companies exhibit traits of resilience, ambition, humility, and adaptability, which are crucial for navigating challenges and seizing opportunities [14][18]. - The article stresses the importance of a company's management in realizing its potential and effectively executing its business model [9][14]. - Companies that prioritize long-term strategies and foster a strong corporate culture are more likely to succeed [19][20]. Group 4: Market Dynamics and Valuation - The article highlights the significance of understanding market dynamics, including the impact of extreme market conditions on investment returns over different time frames [4][20]. - It discusses the importance of recognizing valuation differences and understanding stock price movements to identify investment opportunities [22][23]. - The article also emphasizes the need to adapt to macroeconomic variables and market cycles to optimize investment strategies [22][24].

Core Insights - The Chinese medical equipment industry is advancing rapidly during the 14th Five-Year Plan period, integrating cutting-edge technologies like AI and 5G to create an innovative industrial ecosystem, contributing significantly to the "Healthy China" initiative and enhancing global competitiveness in medical equipment manufacturing [1][4]. Group 1: Technological Breakthroughs - Domestic high-end ultrasound systems are achieving unprecedented image resolution, enabling the detection of micro-level structures for more accurate early disease diagnosis [2]. - The introduction of ultra-weak magnetic imaging devices allows for efficient medical examinations without noise or the need for contrast agents, providing patients with comprehensive reports in under three minutes [2]. - Major advancements include ECMO machines, laparoscopic surgical robots, photon counting spectral CT, and high-performance PET/CT systems, showcasing significant technological achievements in the medical equipment sector [2]. Group 2: Innovation and R&D Investment - Companies are transitioning from being "followers" of international technology to "leaders" with independent innovation capabilities, supported by substantial R&D investments, with firms like Mindray allocating approximately 10% of their revenue to R&D annually [3]. - The number of medical equipment enterprises in China reached 33,400 during the 14th Five-Year Plan, with over 4,000 large-scale companies and around 160 listed firms, indicating a robust growth in the sector [3]. Group 3: New Dynamics in Medical Equipment - The integration of AI with medical imaging devices enhances efficiency by automating patient positioning and reducing unnecessary radiation exposure [4]. - The use of 5G technology in surgical robots enables remote surgeries, allowing doctors to collaborate across vast distances, thus improving access to high-quality medical services [4]. - The market size of China's medical equipment industry surpassed 1 trillion yuan during the 14th Five-Year Plan, fostering the development of six national advanced manufacturing industry clusters [4]. Group 4: Ecosystem Development - Innovative models for medical equipment development are emerging, such as Beijing's innovation center for surgical robots and Chongqing's collaborative approach between enterprises and research institutions [5]. - Shenzhen has established a 4 billion yuan fund for high-end medical equipment, facilitating rapid growth and global expansion for domestic companies [5]. - A comprehensive innovation ecosystem is being developed, supported by national and local initiatives, to enhance the medical equipment sector's growth potential [6].

Core Insights - The article highlights the acceleration of business development (BD) activities in the medical device sector from September to November 2025, with a total of 58 transactions identified across various subfields, including cardiovascular, nuclear medicine, and AI-enabled devices [2][3][4]. Group 1: Mergers and Acquisitions - Mergers and acquisitions have become a prominent form of BD, with companies leveraging capital control and product integration for rapid market positioning [7][8]. - Notable acquisitions include HeartLink's $680 million all-stock acquisition of Micro-Invasive Cardiology, enhancing its structural heart disease and rhythm management capabilities [7]. - Hua'an Zhonghui's acquisition of Bangni Medical marks its entry into the absorbable suture market, indicating a shift in surgical instrument competition towards material innovation [7]. Group 2: Strategic Collaborations - Strategic partnerships have been formed during the China International Import Expo, with companies like Shanghai Pharmaceuticals collaborating with international giants such as Boston Scientific and Medtronic to enhance their supply chain and academic promotion systems [7][8]. - The collaboration between GuoYao Medical and BDI Medical aims to deepen market penetration in the biomedicine and medical device sectors, focusing on compliance and distribution channel construction [13]. Group 3: Cross-Border Cooperation - Cross-border transactions have become more active, with foreign companies establishing local R&D and production systems in China, while domestic firms are exporting their solutions globally [9][10]. - The partnership between Trasis SA and Beijing Pait Biotechnology to establish a joint venture reflects a trend towards localized production and phased integration in the Chinese market [12]. Group 4: Ecosystem Building and Channel Expansion - The integration of supply chains and ecosystem building is a key theme, with companies focusing on collaborative agreements to enhance their market presence [11][15]. - The collaboration between Baxter and Neusoft Medical aims to create a comprehensive surgical solution by integrating their respective technologies [12]. Group 5: AI and Smart Healthcare - AI and data-driven approaches are becoming central to BD collaborations, with companies increasingly focusing on smart healthcare solutions [16][17]. - The partnership between Kefu Medical and Tencent Cloud to develop AI-powered hearing aids exemplifies the trend of integrating technology into healthcare products [21]. Group 6: Research and Diagnostic Synergy - The frequency of research-oriented collaborations is rising, indicating a shift from manufacturing-driven to research-driven industry dynamics [18][19]. - The collaboration between BGI and Infinera to enhance clinical applications of sequencing technology highlights the growing importance of research in driving innovation in the medical device sector [21].

Core Viewpoint - The recent reform in the fund industry emphasizes performance, leading to significant salary reductions for nearly a thousand fund managers if their products underperform by over 10 percentage points compared to benchmarks over the past three years and have negative profit margins [1]. Fund Performance and Management - According to Wind data, the three funds managed by Pang Wenjie have shown substantial negative returns over the past three years, with the North Trust Ruifeng Industrial Upgrade fund underperforming its benchmark by 58.31% and managing a scale of 0.71 billion [2][4]. - The North Trust Ruifeng Preferred Growth fund has underperformed by 45.87% with a scale of 0.23 billion, while the North Trust Ruifeng Health Life Theme fund has underperformed by 39.66% with a scale of 0.90 billion, totaling a management scale of only 1.84 billion [2][4]. Investment Focus and Market Conditions - The funds managed by Pang Wenjie focus on specific themes that have faced industry adjustments, including the new energy sector, consumer goods, and the medical innovation industry [4][5]. - The North Trust Ruifeng Industrial Upgrade fund heavily invests in the new energy supply chain, with major holdings in leading photovoltaic and wind power companies, which have recently experienced significant declines [4]. - The North Trust Ruifeng Preferred Growth fund focuses on the consumer sector, particularly in liquor and food and beverage industries, which have shown mixed performance recently [4][5]. - The North Trust Ruifeng Health Life Theme fund targets the medical innovation sector, which is also facing challenges, with major holdings in medical device companies that have seen declines [4]. Manager's Outlook and Strategy - Pang Wenjie maintains a relatively optimistic outlook for the market, emphasizing the potential recovery of the consumer sector and the benefits of monetary policy changes [5][6]. - He highlights the importance of adapting investment strategies to navigate market style changes and improve fund performance in light of the new salary regulations [6].

风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 12月15日，截止午间收盘，创业50ETF（159682）跌1.42%，报1.459元，成交额1.18亿元。创业50ETF （159682）重仓股方面，宁德时代截止午盘跌1.47%，中际旭创跌0.53%，东方财富涨0.00%，新易盛涨 0.27%，阳光电源跌3.41%，胜宏科技跌4.04%，汇川技术跌2.33%，迈瑞医疗跌0.90%，亿纬锂能跌 2.85%，同花顺跌1.33%。 创业50ETF（159682）业绩比较基准为创业板50指数收益率，管理人为景顺长城基金管理有限公司，基 金经理为汪洋、张晓南，成立（2022-12-23）以来回报为48.08%，近一个月回报为3.19%。 来源：新浪基金∞工作室 ...

Core Insights - The article discusses the ESG-V rating system applied to listed companies in Guangdong, emphasizing its role in assessing the sustainability and investment value of companies in China's economic hubs [1][2][3] Group 1: ESG-V Rating Framework - The ESG-V rating system integrates corporate value into traditional ESG assessments, focusing on objective, industry-specific, and verifiable metrics [1][2] - The evaluation covers four dimensions: Environment (E), Social (S), Governance (G), and Value (V), aiming to provide a comprehensive view of corporate sustainability and investment potential [1][3] Group 2: Environmental (E) Assessment - The environmental evaluation extends beyond pollution control to assess the overall environmental impact across the entire supply chain, including raw material sourcing and product lifecycle [1] - Companies are identified based on their ability to innovate with green technologies and collaborate within the industry to build long-term competitive advantages [1] Group 3: Social (S) Assessment - The social dimension focuses on the legality and authenticity of corporate operations, scrutinizing issues like financial fraud and information disclosure violations [1][2] - It emphasizes the fundamental legal responsibilities and social trust obligations that companies owe to investors, employees, and the public [1] Group 4: Governance (G) Assessment - Governance is defined as "corporate oversight," expanding the evaluation to include relationships with all stakeholders, particularly in tax compliance and debt obligations [2] - The framework incorporates the business environment into governance assessments, highlighting the importance of positive interactions with regulatory bodies [2] Group 5: Value (V) Assessment - The value dimension innovatively integrates corporate value into the ESG framework, utilizing the "Ji'an Pricing" model to assess long-term investment value and valuation rationality [2] - This allows investors to evaluate companies' sustainability capabilities alongside their potential for investment returns within a unified framework [2] Group 6: Guangdong Listed Companies Evaluation - A total of 790 companies were evaluated in Guangdong, with 8 achieving the highest rating of AAA, including notable firms like Haitai Flavor Industry and China Merchants Bank [3][5] - The rating system categorizes companies into ten levels from AAA to D, with 35 companies rated AA and 122 rated A, indicating a solid foundation for sustainable development and value management in Guangdong [3][5]

Core Insights - Jinan International Medical Center is transforming into a national-level health industry hub, leveraging policy benefits, financial support, and high-end medical resources to establish a "high-end, specialized, and international" development pattern by 2025 [1][3][10] Medical Services - The Shandong Proton Center within the medical center has treated nearly 2,000 patients, ranking first in the 2024-2025 China Proton and Heavy Ion Center rankings, showcasing advancements in precision radiation therapy [2] Technological Innovation - The medical center is actively participating in major medical technology exhibitions, introducing innovative technologies such as Hi-tACS for treating neuropsychiatric disorders and AI-assisted diagnostic systems, enhancing the development of precision medicine [4][5] Health Industry Development - The Jinan government is supporting the establishment of a national medical center and accelerating the development of medical parks, ensuring efficient招商 (investment attraction) processes through comprehensive management strategies [6][7] International Cooperation - The medical center is expanding its international collaboration by signing agreements with institutions in South Korea, focusing on various medical fields, and hosting annual Sino-Korean health industry cooperation conferences [8] Resource Support - The Shandong government has introduced tailored policies to support the medical center, including financial backing through various funds, facilitating the approval of medical devices, and enhancing project execution efficiency [9][10]